Do Early Phase Oncology Trials Predict Clinical Efficacy in Subsequent Biomarker-Enriched Phase III Randomized Trials?

被引:0
作者
Suji Udayakumar
Sasha Thomson
Albiruni R. Abdul Razak
Kelvin K. W. Chan
机构
[1] Sunnybrook Research Institute,Division of Medical Oncology and Hematology, Drug Development Program, Princess Margaret Cancer Centre
[2] University Health Network,Department of Medicine
[3] University of Toronto,Odette Cancer Centre
[4] Sunnybrook Health Sciences Centre,undefined
[5] Canadian Centre for Applied Research in Cancer Control,undefined
来源
Targeted Oncology | 2022年 / 17卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:665 / 674
页数:9
相关论文
共 99 条
  • [1] Billingham L(2016)Research methods to change clinical practice for patients with rare cancers Lancet Oncol 17 e70-e80
  • [2] Malottki K(2005)Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens J Clin Oncol 23 6982-6991
  • [3] Steven N(2020)Response rates and durations of response for biomarker-based cancer drugs in nonrandomized versus randomized trials JNCCN J Natl Compr Cancer Netw 18 36-43
  • [4] Zia MI(2014)Approval after phase I: ceritinib runs the three-minute mile Oncologist 19 577-578
  • [5] Siu LL(2013)Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study Lancet Oncol 14 38-47
  • [6] Pond GR(2017)Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: the SELECT-1 randomized clinical trial JAMA 317 1844-1853
  • [7] Chen EX(2016)Sufficiency of single-arm studies to support registration of targeted agents in molecularly selected patients with cancer: lessons from the clinical development of crizotinib Clin Transl Sci 9 63-73
  • [8] Gyawali B(2012)Role of randomized phase III trials in an era of effective targeted therapies Nat Rev Clin Oncol 9 208-214
  • [9] D’Andrea E(2016)Benefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive metastatic non-small cell lung cancer Oncologist 21 974-980
  • [10] Franklin JM(2018)Without randomized studies, the costeffectiveness of a therapy cannot be known Ann Oncol 29 527-529